Lisa Whims Squires, DO
Pulmonary Disease · Clearwater, FLNPI 1831133446
Payments from drug & device makers
Across 369 payments — averaging $30.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$4K
- Jazz Pharmaceuticals Inc.$2K
- Harmony Biosciences LLC$2K
- GSK$929
- AstraZeneca$511
- Avadel CNS Pharmaceuticals, LLC$440
- plus $1K from 20 others
What the payments were for
- Consulting fees$2002%
- Food & beverage$6,48158%
- Education$4674%
- Other$4,08636%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 12 | $4,286 |
| Jazz Pharmaceuticals Inc. | 86 | $1,928 |
| Harmony Biosciences LLC | 87 | $1,663 |
| GSK | 66 | $929 |
| AstraZeneca | 27 | $511 |
| Avadel CNS Pharmaceuticals, LLC | 11 | $440 |
| Mylan Specialty L.p. | 13 | $287 |
| Axsome Therapeutics, Inc. | 8 | $159 |
| Idorsia Pharmaceuticals US Inc | 9 | $143 |
| UCB, Inc. | 6 | $119 |
| Boehringer Ingelheim | 6 | $99 |
| Fisher & Paykel Healthcare Inc | 5 | $97 |
| Resmed Corp | 4 | $89 |
| Eisai Inc. | 6 | $89 |
| Arbor Pharmaceuticals, Inc. | 6 | $79 |
| Azurity Pharmaceuticals, Inc. | 3 | $55 |
| Merck | 2 | $45 |
| Bayer | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Inogen, Inc. | 2 | $30 |
| Aytu Biopharma, Inc. | 1 | $25 |
| Insmed, Inc. | 1 | $22 |
| 3b Medical, Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (8269) DreamStation Cpap$4,086
- LUMRYZ$200
How this compares
$11,234 in reported general payments places this provider in the 65th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $246,879 |
| XyremSodium Oxybate | 11 | $197,230 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $78,882 |
| BelsomraSuvorexant | 51 | $27,467 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $22,264 |
| HorizantGabapentin Enacarbil | 15 | $21,231 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $19,104 |
| NeuproRotigotine | 13 | $12,105 |
| Spiriva RespimatTiotropium Bromide | 16 | $10,061 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $8,121 |
| DuleraMometasone/Formoterol | 16 | $7,372 |
| Modafinil | 75 | $4,818 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $4,750 |
| Ropinirole Hcl | 145 | $3,853 |
| Azelastine Hcl | 123 | $3,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $929 | $128,371180 claims |
| MerckBelsomra, Dulera | $45 | $34,83967 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $79 | $21,23115 claims |
| UCB, Inc.Neupro | $119 | $12,10513 claims |
| Boehringer IngelheimSpiriva Respimat | $99 | $10,06116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Clearwater
- Francis AverillClearwater$6.3M
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.